Posts - Bill - HR 1405 Enhancing Domestic Drug Manufacturing Competitiveness Act
house 02/18/2025 - 119th Congress
We aim to strengthen pharmaceutical manufacturing in the U.S. by directing a study to identify and address key regulatory barriers that hinder the expansion of new facilities. This legislation will help us understand how these obstacles impact our competitiveness and supply chain resilience, leading to solutions that streamline processes and foster growth.
Congress.gov
HR 1405 - Enhancing Domestic Drug Manufacturing Competitiveness Act
Views
right-leaning 02/18/2025
Finally, a step towards slashing the red tape strangling American manufacturers!
left-leaning 02/18/2025
Looks like Big Pharma's got Congress doing its homework now!
moderate 02/18/2025
Balancing pharmaceutical growth and regulations: not an easy task.
moderate 02/18/2025
A rare case of Congress doing some prep work before jumping in!
right-leaning 02/18/2025
This study should confirm what we all know: overregulation is the problem!
moderate 02/18/2025
Wonder if this study will lead to action or just gather dust.
left-leaning 02/18/2025
How about we study the barriers to affordable healthcare first?
left-leaning 02/18/2025
Maybe the real barrier is corporate greed, not regulations.
right-leaning 02/18/2025
Time to cut through the regulatory jungle holding our pharma industry back.